BACKGROUND: Mutations in the BRCA genes increase the risk of breast cancer. Valid estimates of the magnitude of the lifetime risk of breast cancer in BRCA gene mutation carriers are needed for genetic counseling. Recent results suggest that penetrance has increased in recent birth cohorts. We examined the cumulative breast cancer incidence and mortality before age 70 over a diagnosis period of 80 years in Icelandic women who carried the BRCA2 founder mutation 999del5. METHODS: Information on all breast cancers diagnosed in Iceland since 1911 was obtained from the Icelandic Cancer Registry. Mutation status was determined by molecular analysis of tissue samples for 847 breast cancer probands who were diagnosed from 1921 through 1985 and selected without knowledge of family history of breast cancer. We estimated the cumulative incidence and mortality from breast cancer before age 70 years in BRCA2 mutation carriers from the observed risks in first-degree relatives who were classified according to mutation status of probands and followed-up through 2002. Poisson modeling of these risks was also carried out. All statistical tests were two-sided. RESULTS: Of the 847 probands, 88 carried the BRCA2 999del5 mutation and 759 did not. According to Poisson modeling, the cumulative incidence of breast cancer before age 70 years in mutation carriers increased from 18.6% (95% CI = 11.0% to 29.5%) in calendar year 1920 to 71.9% (95% CI = 45.9% to 100%) in 2002 (P < .001); in relatives of probands who did not carry the BRCA2 mutation and in the general Icelandic population incidence increased over the same period from 2.6% to 10.7% and from 1.8% to 7.5%, respectively (all increases of approximately fourfold). During the same period, the cumulative risk of death from breast cancer before age 70 years for BRCA2 mutation carriers increased from 12.1% (95% CI = 5.3% to 23.9%) to 26.9% (95% CI = 10.9% to 55.5%) (P = .08). However, because the probands were breast cancer patients and not a random sample from the population, some bias in the estimation of time trends in penetrance cannot be ruled out. CONCLUSIONS: The results indicate that the penetrance of the Icelandic BRCA2 founder mutation increased nearly fourfold in 80 years, whereas the risk of death from breast cancer before age 70 years increased only approximately twofold. Changes in penetrance with time should be considered when penetrance is estimated.
BACKGROUND: Mutations in the BRCA genes increase the risk of breast cancer. Valid estimates of the magnitude of the lifetime risk of breast cancer in BRCA gene mutation carriers are needed for genetic counseling. Recent results suggest that penetrance has increased in recent birth cohorts. We examined the cumulative breast cancer incidence and mortality before age 70 over a diagnosis period of 80 years in Icelandic women who carried the BRCA2 founder mutation 999del5. METHODS: Information on all breast cancers diagnosed in Iceland since 1911 was obtained from the Icelandic Cancer Registry. Mutation status was determined by molecular analysis of tissue samples for 847 breast cancer probands who were diagnosed from 1921 through 1985 and selected without knowledge of family history of breast cancer. We estimated the cumulative incidence and mortality from breast cancer before age 70 years in BRCA2 mutation carriers from the observed risks in first-degree relatives who were classified according to mutation status of probands and followed-up through 2002. Poisson modeling of these risks was also carried out. All statistical tests were two-sided. RESULTS: Of the 847 probands, 88 carried the BRCA2999del5 mutation and 759 did not. According to Poisson modeling, the cumulative incidence of breast cancer before age 70 years in mutation carriers increased from 18.6% (95% CI = 11.0% to 29.5%) in calendar year 1920 to 71.9% (95% CI = 45.9% to 100%) in 2002 (P < .001); in relatives of probands who did not carry the BRCA2 mutation and in the general Icelandic population incidence increased over the same period from 2.6% to 10.7% and from 1.8% to 7.5%, respectively (all increases of approximately fourfold). During the same period, the cumulative risk of death from breast cancer before age 70 years for BRCA2 mutation carriers increased from 12.1% (95% CI = 5.3% to 23.9%) to 26.9% (95% CI = 10.9% to 55.5%) (P = .08). However, because the probands were breast cancerpatients and not a random sample from the population, some bias in the estimation of time trends in penetrance cannot be ruled out. CONCLUSIONS: The results indicate that the penetrance of the Icelandic BRCA2 founder mutation increased nearly fourfold in 80 years, whereas the risk of death from breast cancer before age 70 years increased only approximately twofold. Changes in penetrance with time should be considered when penetrance is estimated.
Authors: Janet R Vos; Li Hsu; Richard M Brohet; Marian J E Mourits; Jakob de Vries; Kathleen E Malone; Jan C Oosterwijk; Geertruida H de Bock Journal: J Clin Oncol Date: 2015-07-06 Impact factor: 44.544
Authors: V Stefansdottir; H Skirton; O Th Johannsson; H Olafsdottir; G H Olafsdottir; L Tryggvadottir; J J Jonsson Journal: Fam Cancer Date: 2019-04 Impact factor: 2.375
Authors: Ana Peixoto; Natália Salgueiro; Catarina Santos; Graça Varzim; Patrícia Rocha; Maria José Soares; Deolinda Pereira; Helena Rodrigues; Maria José Bento; António Fráguas; Graça Moura; Fernando Regateiro; Sérgio Castedo; Manuel R Teixeira Journal: Fam Cancer Date: 2006-07-07 Impact factor: 2.375
Authors: Mia M Gaudet; Tomas Kirchhoff; Todd Green; Joseph Vijai; Joshua M Korn; Candace Guiducci; Ayellet V Segrè; Kate McGee; Lesley McGuffog; Christiana Kartsonaki; Jonathan Morrison; Sue Healey; Olga M Sinilnikova; Dominique Stoppa-Lyonnet; Sylvie Mazoyer; Marion Gauthier-Villars; Hagay Sobol; Michel Longy; Marc Frenay; Frans B L Hogervorst; Matti A Rookus; J Margriet Collée; Nicoline Hoogerbrugge; Kees E P van Roozendaal; Marion Piedmonte; Wendy Rubinstein; Stacy Nerenstone; Linda Van Le; Stephanie V Blank; Trinidad Caldés; Miguel de la Hoya; Heli Nevanlinna; Kristiina Aittomäki; Conxi Lazaro; Ignacio Blanco; Adalgeir Arason; Oskar T Johannsson; Rosa B Barkardottir; Peter Devilee; Olofunmilayo I Olopade; Susan L Neuhausen; Xianshu Wang; Zachary S Fredericksen; Paolo Peterlongo; Siranoush Manoukian; Monica Barile; Alessandra Viel; Paolo Radice; Catherine M Phelan; Steven Narod; Gad Rennert; Flavio Lejbkowicz; Anath Flugelman; Irene L Andrulis; Gord Glendon; Hilmi Ozcelik; Amanda E Toland; Marco Montagna; Emma D'Andrea; Eitan Friedman; Yael Laitman; Ake Borg; Mary Beattie; Susan J Ramus; Susan M Domchek; Katherine L Nathanson; Tim Rebbeck; Amanda B Spurdle; Xiaoqing Chen; Helene Holland; Esther M John; John L Hopper; Saundra S Buys; Mary B Daly; Melissa C Southey; Mary Beth Terry; Nadine Tung; Thomas V Overeem Hansen; Finn C Nielsen; Mark H Greene; Mark I Greene; Phuong L Mai; Ana Osorio; Mercedes Durán; Raquel Andres; Javier Benítez; Jeffrey N Weitzel; Judy Garber; Ute Hamann; Susan Peock; Margaret Cook; Clare Oliver; Debra Frost; Radka Platte; D Gareth Evans; Fiona Lalloo; Ros Eeles; Louise Izatt; Lisa Walker; Jacqueline Eason; Julian Barwell; Andrew K Godwin; Rita K Schmutzler; Barbara Wappenschmidt; Stefanie Engert; Norbert Arnold; Dorothea Gadzicki; Michael Dean; Bert Gold; Robert J Klein; Fergus J Couch; Georgia Chenevix-Trench; Douglas F Easton; Mark J Daly; Antonis C Antoniou; David M Altshuler; Kenneth Offit Journal: PLoS Genet Date: 2010-10-28 Impact factor: 5.917
Authors: Rodrigo Santa Cruz Guindalini; Andrew Song; James D Fackenthal; Olufunmilayo I Olopade; Dezheng Huo Journal: Cancer Date: 2016-03-15 Impact factor: 6.860